Surmodics INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

8 Aug 2025

SRDX

10-Q: Surmodics Q3 Loss Narrows Amid Merger Uncertainty

Surmodics reports a narrower quarterly net loss but faces revenue declines and ongoing FTC litigation challenging its proposed acquisition.

30 Apr 2025

SRDX

Surmodics INC

10-Q: Surmodics Reports Q2 2025 Results Amidst FTC Litigation Over Proposed Acquisition

Surmodics' Q2 2025 results reveal a revenue decrease and operating loss, overshadowed by ongoing legal challenges from the FTC regarding its acquisition by BCE Parent, LLC.

30 Jan 2025

SRDX

Surmodics INC

10-Q: Surmodics Reports Q1 2025 Results, Impacted by Merger Costs and SurVeil DCB Revenue Decline

Surmodics' first quarter of fiscal year 2025 saw a net loss of $3.651 million, impacted by merger-related charges and a decrease in SurVeil DCB product sales.

31 Jul 2024

SRDX

Surmodics INC

10-Q: Surmodics Reports Q3 2024 Results Amidst Pending Acquisition

Surmodics' Q3 2024 results show a significant revenue decrease due to a prior year milestone payment, alongside increased product sales and a pending merger agreement.

1 May 2024

SRDX

Surmodics INC

10-Q: Surmodics Reports Q2 2024 Results: Revenue Growth Driven by Medical Device Sales

Surmodics saw a significant increase in revenue in the second quarter of 2024, primarily driven by growth in its Medical Device segment, particularly from the commercial launch of its SurVeil drug-coated balloon.

1 Feb 2024

SRDX

Surmodics INC

10-Q: Surmodics Reports Q1 2024 Results: Revenue Growth Driven by Medical Device Sales

Surmodics' first quarter of fiscal year 2024 saw a 23% increase in revenue, primarily driven by strong performance in the Medical Device segment.